JP2023541379A5 - - Google Patents

Info

Publication number
JP2023541379A5
JP2023541379A5 JP2023513936A JP2023513936A JP2023541379A5 JP 2023541379 A5 JP2023541379 A5 JP 2023541379A5 JP 2023513936 A JP2023513936 A JP 2023513936A JP 2023513936 A JP2023513936 A JP 2023513936A JP 2023541379 A5 JP2023541379 A5 JP 2023541379A5
Authority
JP
Japan
Prior art keywords
approximately
less
dose
substituted
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023513936A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023541379A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/048540 external-priority patent/WO2022051305A1/en
Publication of JP2023541379A publication Critical patent/JP2023541379A/ja
Publication of JP2023541379A5 publication Critical patent/JP2023541379A5/ja
Pending legal-status Critical Current

Links

JP2023513936A 2020-09-01 2021-08-31 神経系の疾患及び障害を改善するための組成物及び方法 Pending JP2023541379A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063073353P 2020-09-01 2020-09-01
US63/073,353 2020-09-01
US202163212077P 2021-06-17 2021-06-17
US63/212,077 2021-06-17
PCT/US2021/048540 WO2022051305A1 (en) 2020-09-01 2021-08-31 Compositions and methods for improving neurological diseases and disorders

Publications (2)

Publication Number Publication Date
JP2023541379A JP2023541379A (ja) 2023-10-02
JP2023541379A5 true JP2023541379A5 (https=) 2024-09-09

Family

ID=80491939

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023513936A Pending JP2023541379A (ja) 2020-09-01 2021-08-31 神経系の疾患及び障害を改善するための組成物及び方法

Country Status (8)

Country Link
US (1) US20230263749A1 (https=)
EP (1) EP4208159A4 (https=)
JP (1) JP2023541379A (https=)
KR (1) KR20230107211A (https=)
AU (1) AU2021337583A1 (https=)
CA (1) CA3189243A1 (https=)
MX (1) MX2023002350A (https=)
WO (1) WO2022051305A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022185255A1 (en) 2021-03-03 2022-09-09 Lenovo (Singapore) Pte. Ltd. Beam failure detection using multiple sets of reference signals
WO2024137506A1 (en) * 2022-12-21 2024-06-27 Curasen Therapeutics, Inc. Compositions and methods for improving neurological diseases and disorders
US20250107713A1 (en) * 2023-09-29 2025-04-03 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Confirming Iboga Alkaloid Treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3952101A (en) * 1975-04-14 1976-04-20 Smithkline Corporation α-Amino methyl-5-hydroxy-2-pyridinemethanols
NZ226991A (en) * 1987-11-27 1992-03-26 Merck & Co Inc Alpha-heterocyclically-substituted ethanolamines and use as animal growth promotors
US5264459A (en) * 1992-07-13 1993-11-23 Arch Development Corporation Use of β-adrenergic agonists to treat patients with demyelinating or autoimmune diseases
GB2356197A (en) * 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
CN1469876A (zh) * 2000-10-20 2004-01-21 �Ʒ� α-芳基乙醇胺及其用作β-3肾上腺素能受体激动剂的用途
US20080033027A1 (en) * 2005-03-21 2008-02-07 Vicus Therapeutics Spe 1, Llc Drug combination pharmaceutical compositions and methods for using them
US9320724B2 (en) * 2013-02-13 2016-04-26 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognition and increasing dendritic complexity in humans with down syndrome and compositions therefor
WO2018195473A1 (en) * 2017-04-20 2018-10-25 The Brigham And Women's Hospital, Inc. Combinations including beta-adrenoreceptor agonists for treatment of parkinson's disease and movement disorders
CA3100848A1 (en) * 2018-06-14 2019-12-19 Curasen Therapeutics, Inc. Methods for improving neurological diseases and disorders
EP3806957A4 (en) * 2018-06-14 2022-03-16 Curasen Therapeutics, Inc. METHODS OF DIAGNOSIS, MONITORING AND TREATMENT OF NEUROLOGICAL DISEASES AND DISORDERS
JP7682097B2 (ja) * 2019-03-27 2025-05-23 キュラセン セラピューティクス インコーポレイテッド ベータアドレナリンアゴニスト及びそれを使用する方法
WO2021081292A1 (en) * 2019-10-25 2021-04-29 Curasen Therapeutics, Inc. METHODS FOR TREATING NEUROLOGICAL DISORDERS WITH α1A-AR PARTIAL AGONISTS
CA3161376A1 (en) * 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders
MX2022015165A (es) * 2020-06-04 2023-03-01 Curasen Therapeutics Inc Formas y composiciones de un agonista beta adrenégico.

Similar Documents

Publication Publication Date Title
JP2023507408A5 (https=)
JP2023541379A5 (https=)
JP4637351B2 (ja) 神経変性疾患の処置法
JP6517827B2 (ja) イソインドリン組成物および神経変性疾患の治療方法
JP2021527712A5 (https=)
KR101581289B1 (ko) 모노아민 재흡수 억제제로서 페닐 치환된 시클로알킬아민
JP2008520589A5 (https=)
JP2004515477A (ja) Ｎｍｄａレセプターアンタゴニストを用いて神経精神医学的障害を処置するための方法
CN111039939B (zh) 用作蛋白质聚集抑制剂的杂芳基酰胺
RU2007119585A (ru) Производные рапамицина и их применение при лечении неврологических заболеваний
AU2020206826B2 (en) Ketamine pamoate and use thereof
JP2017508736A (ja) びまん性大細胞型ｂ細胞リンパ腫の予防および／または治療剤
JP2025032222A (ja) Ｂｃｎ０５７及びｂｃｎ５１２を用いる治療方法
JP2023525359A (ja) Ｓａｒｓの治療のための化合物
JP2023541379A (ja) 神経系の疾患及び障害を改善するための組成物及び方法
CN100502847C (zh) 含有取代喹啉和取代二苯砜的组合物及其制药用途
US12091378B2 (en) Therapeutics for central nervous system disorders
JPH0466477B2 (https=)
JP2021512958A (ja) 神経変性疾患を治療するための医薬及びその使用
PT1551412E (pt) COMPOSIÇÕES FARMACjUTICAS PARA O TRATAMENTO DE DOENÇAS ASSOCIADAS ÀS NEUROTROFINAS
JPH08512305A (ja) 神経変性疾患の治療を目的とする医薬生成物の製造のためのエファロキサンおよびその誘導体の使用
EP4582412A1 (en) Chiral gamma lactam derivative or pharmaceutically acceptable salt thereof, and preparation method therefor
JP2021535093A (ja) 緑内障の治療のためのカルパイン−２選択的阻害剤化合物
US12152008B2 (en) Cyclopentaimidazolones for the treatment of cancer
US10870633B2 (en) Types of C-3 substituted kynurenic acid derivatives with improved neuroprotective activity